GlassScriptPhysician profile
Sara Taylor
NPI 1528724960
$2,513.28
in general payments reported to CMS, 2019-2025
18 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $629 · 2024: $472 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.55 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exactech, INC. | $628.58 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.99 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $298.87 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $285.39 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $171.99 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $134.72 | 2025 | Auvelity |
| Alkermes, INC. | $101.30 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $92.75 | 2025 | |
| Abbvie INC. | $86.75 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $68.51 | 2025 | Austedo Xr, Uzedy |
| Corium, LLC | $57.45 | 2025 | Azstarys |
| Sage Therapeutics, LLC | $49.49 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $44.69 | 2024-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $40.36 | 2024 | |
| Indivior INC. | $24.99 | 2024 | Sublocade |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $18.72 | 2025 | Relexxii |
| Lundbeck LLC | $16.76 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $13.97 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.